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Abstract
Background: Understanding the origin and spread of mutations associated with drug resistance, especially in the
context of combination therapy, will help guide strategies to halt and prevent the emergence of resistance.
Unfortunately, studies have assessed these complex processes when resistance is already highly prevalent. Even
further, information on the evolutionary dynamics leading to multidrug-resistant parasites is scattered and limited
to areas with low or seasonal malaria transmission. This study describes the dynamics of strong selection for
mutations conferring resistance against sulphadoxine-pyrimethamine (SP), a combination therapy, in western Kenya
between 1992 and 1999, just before SP became first-line therapy (1999). Importantly, the study is based on
longitudinal data, which allows for a comprehensive analysis that contrasts with previous cross-sectional studies
carried out in other endemic regions.
Methods: This study used 236 blood samples collected between 1992 and 1999 in the Asembo Bay area of Kenya.
Pyrosequencing was used to determine the alleles of dihydrofolate reductase (dhfr) and dihydropterote synthase
(dhps) genes. Microsatellite alleles spanning 138 kb around dhfr and dhps, as well as, neutral markers spanning
approximately 100 kb on chromosomes 2 and 3 were characterized.
Results: By 1992, the South-Asian dhfr triple mutant was already spreading, albeit in low frequency, in this
holoendemic Kenyan population, prior to the use of SP as a first-line therapy. Additionally, dhfr triple mutant alleles
that originated independently from the predominant Southeast Asian lineage were present in the sample set.
Likewise, dhps double mutants were already present as early as 1992. There is evidence for soft selective sweeps of
two dhfr mutant alleles and the possible emergence of a selective sweep of double mutant dhps alleles between
1992 and 1997. The longitudinal structure of the dataset allowed estimation of selection pressures on various dhfr
and dhps mutants relative to each other based on a theoretical model tailored to P. falciparum. The data indicate
that drug selection acted differently on the resistant alleles of dhfr and dhps, as evidenced by fitness differences.
Thus a combination drug therapy such as SP, by itself, does not appear to select for “multidrug"-resistant parasites
in areas with high recombination rate.
Conclusions: The complexity of these observations emphasizes the importance of population-based studies to
evaluate the effects of strong drug selection on Plasmodium falciparum populations.
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Background
The massive use of drugs for treating Plasmodium falci-
parum malaria has selected for mutations that confer
resistance in endemic areas worldwide, rendering tradi-
tional anti-malarial drugs ineffective in vast regions of
the globe [1,2]. Artemisinin combination therapy (ACT)
is now being used in many endemic areas; however, there
are concerns that mutations conferring resistance against
ACT could also emerge [3,4]. Understanding such com-
plex evolutionary processes, especially in the context of
combination therapies, is a matter of great interest. Valu-
able information about such dynamics can be obtained
by retrospectively investigating the rise of resistance
against sulphadoxine-pyrimethamine (SP), a combination
drug therapy that has been widely used and for which the
molecular basis of resistance is well known.
SP acts as an inhibitor of the P. falciparum folic acid
pathway, and point mutations in two genes, dihydrofolate
reductase (DHFR) and dihydropteroate synthetase
(DHPS), confer resistance to SP [5]. Point mutations at
dhfr codons 50, 51, 59, 108 and 164 act synergistically to
increase resistance to pyrimethamine. Of note, S108N
has a low level of resistance, the double mutants N51I/
S108N and C59R/S108N have moderate levels of resis-
tance, the triple mutant N51I/C59R/S108N has a higher
level, and the quadruple mutant parasite (N51I/C59R/
S108N/I164L) is considered to be resistant to the effects
of pyrimethamine [6,7]. Similarly, mutations at dhps
codons 436, 437, 540, 581 and 613 act synergistically to
increase the level of resistance to sulphadoxine. Simply,
the mutations S436A and A437G alone confer a low level
of resistance, and when in combination with K540E and/
or A581G and/or A613S/T the parasite has an increased
level of resistance to sulphadoxine [1,8].
The evolution of drug resistance is further complicated
by the fact that resistant alleles may have multiple origins
intertwined with migration patterns among P. falciparum
populations; such complex dynamics are still poorly
understood. There is compelling evidence indicating a
common origin for highly resistant pyrimethamine alleles
across Southeast Asia and at a few sites in Africa [9-14];
however, additional, novel low frequency lineages for the
triple mutant (51I/59R/108 N) dhfr allele have been docu-
mented in Cameroon and also in western Kenyan [14,15].
Similarly, recent studies from sites across Africa and Asia
show multiple independent origins of mutations at dhps
[16-18]. However, the patterns for dhps highlight different
evolutionary processes than those for dhfr. Thus, SP-
induced selection on resistance-associated mutations may
differ for the two genes and across different endemic
regions. Hence, reliable estimates of selective parameters
for various dhfr and dhps mutations are highly desirable.
A few studies have addressed the genetic conse-
quences of SP drug selection, yet the temporal dynamics
of mutations are rarely investigated in both loci. Indeed,
patterns consistent with selective sweeps of highly resis-
tant dhfr alleles have been reported in multiple popula-
tions [9,19,20], but there are only a few studies on dhps
[14,17,18,20]. Despite the limited evidence, dhps shows a
clear pattern of reduced diversity in multiple popula-
tions, indicating an increase in mutant alleles conferring
resistance to sulphadoxine. Notably, the patterns of the
selective sweeps in dhps and dhfr appear to be different,
providing evidence that the strength of selection is not
the same on both loci [14,20]. However, all these studies
are based on cross-sectional data and measures of the
strength of drug selection are limited. Attempts to infer
the strength of selection have been made for dhfr [9,21]
but such estimates focused only on the proportion of
clinical failures, an indirect line of evidence that does
not consider the actual frequency of resistant mutations
and may lead to inaccurate predictions. A direct com-
parison of the selective strengths on dhfr and dhps dur-
ing the early stages of the onset of clinical resistance is
still missing. Indeed, estimates of drug selection have
not been obtained from molecular data. Moreover, pat-
tern of selective sweeps studied so far just indicate drug
selection but the importance of linking estimates of
selection parameters with the pattern of the sweep have
been neglected.
Here, a population-based characterization and analysis
of genetic signatures around dhfr and dhps from samples
collected in western Kenya from 1992-1999 was con-
ducted. At the time these samples were collected, SP had
been exerting selective pressure on P. falciparum popula-
tions since the 1980s. SP was introduced in Kenya as a
second-line treatment for uncomplicated malaria in 1983
and as a first-line treatment in 1999 [22,23]. However,
clinical SP resistance was noted as early as 1982 [23].
Thus, this study captures some of the early events in the
dynamics of drug-resistant mutations in the local P. falci-
parum population. Even before SP was chosen as a first-
line treatment, all alleles in the population had dhfr
mutations associated with pyrimethamine resistance. In
contrast, sulphadoxine-sensitive alleles at dhps were still
present while resistant double-mutant alleles were
increasing in frequency. The longitudinal data, allowed
inferences of the selective strengths on various mutations
at dhfr and dhps based on a theoretical model tailored to
P. falciparum. Overall, these investigations highlight the
differences in selective pressures on these two loci, when
the drugs were part of a combination drug therapy.
Methods
Study subjects
Two hundred thirty-six blood samples collected from
the Asembo Bay Cohort Project, from the years 1992-
1999 [24], were analysed. This study was approved by
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the ethical committee of (Institutional Review Board)
CDC and the Kenya National Ethics Review Committee.
The participants provided written informed consent. In
short, this was a longitudinal study conducted between
1992 and 1999 in western Kenya, a holo-endemic area
of intense transmission estimated at approximately 300
infective bites per person per year [25]. Blood samples
were taken from mother-infant pairs and other siblings
less than five years old once per month until the chil-
dren turned five years old. Malaria parasitaemia was
treated with SP.
DNA isolation and genotyping methods
DNA was isolated from whole blood using the
QIAamp® DNA Mini Kit (Qiagen, Valencia, CA, USA).
All samples were genotyped for P. falciparum mutations
at dhfr codons 50, 51, 59, 108, and 164 and dhps codons
436, 437, 540, 581, and 613 by pyrosequencing as pre-
viously described [20,26].
Microsatellite characterization
Microsatellite characterization was conducted on all sam-
ples. Samples were assayed for 18 microsatellite loci that
span 138 kb on chromosome 4 around dhfr [9-11], 18
loci that span 138 kb on chromosome 8 around dhps
[19], five loci on chromosome 2 that span 101 kb, and
four loci on chromosome 3 that span 94 kb [20]. The
microsatellites used around dhfr are at -89, -58, -30, -17,
-10, -7.5, -5.3, -4.5, -4.4, -3.8, -1.2, -0.3, 0.2, 0.52, 1.48,
4.05, 5.87, 30.3, and 50 kb; where negative numbers refer
to positions 5’ to the gene and positive numbers refer to
positions 3’ to the gene. The microsatellites used around
dhps are at -72.7, -34.5, -18.7, -11, -7.4, -2.8, -1.5, -0.132,
0.034, 0.5, 1.4, 6.4, 9, 16.3, 22.8, 36, 49.5, and 66.1 kb.
The loci around dhps have been previously published
[19,20]; however, it was recently brought to the authors’
attention that the orientation of the microsatellite loci
along chromosome 8 around dhps was incorrect in [20]:
loci that have been reported previously as 5’ to dhps are
actually 3’ and vice versa. To avoid any confusion, the
corrections along with previously published positions and
primers are in Additional file 1: Table S1. The correct
positions of dhps loci have been used throughout this
manuscript.
The microsatellites used on chromosome 2 are at 302,
313, 319, 380, and 403 kb. The microsatellites used on
chromosome 3 are at 335, 363, 383, and 429 kb. The PCR
primers for 403 kb chromosome 2 are 5’-AAATA-
TAAATCTTCTTCTTCTTTTTT-3’ (forward) and 5’-
TAGAGAAATAAATATATCCAT-3’ (reverse); and for
363 kb chromosome 3 are 5’-CAAAAATGAAAAAT-
GAAAAGG-3’ (forward) and 5’-TAAAGGGTGCGCA-
TATCAAT-3’ (reverse). All remaining microsatellite PCR
primers are detailed in [20]. Single reaction PCR and ther-
mal cycling conditions are detailed in [9]; and nested PCR
reactions and thermal cycling conditions are detailed in
[10]. PCR products were separated on Applied Biosystems
3100 capillary sequencer and scored using GeneMapper®
software v3.7 (Applied Biosystems, Foster City, CA, USA).
Genetic variation per locus and allele
The genetic variation for each microsatellite locus was
measured by calculating the expected heterozygosity
(He) and number of alleles per locus (L). He was calcu-
lated for each locus as He = n/ (n− 1)
[
1−
∑
p2i
]
,
where n is the number of isolates sampled and
pi is the frequency of the ith allele (i = 1,...,L).
The sampling variance for He was calculated as
2 (n− 1) /n3
[
2(n− 2)
[∑
p3i −
(∑
p2i
)2]]
[19,21]. He
was calculated using all alleles that occurred in the
respective group including those in isolates that carried
more than one microsatellite allele.
He, was also calculated for microsatellite loci associated
with specific dhfr and dhps mutant alleles. For dhfr
alleles, only samples with single ‘clone’ infections of the
respective mutant allele were used. This guarantees that
the microsatellite variation is linked to the respective
allele. The pattern of variation present, before the occur-
rence of a beneficial mutation, should be reflected by He
among wildtype alleles; however, since sensitive wildtype
alleles were only present at marginal frequencies an esti-
mate of He could not be calculated. As a proxy to esti-
mate the initial variation, He was calculated among non-
triple mutant dhfr alleles. For this estimation, all mixed
infections that did not contain the 51I/59R/108 N triple
mutant (e.g. an isolate with mixed codon 51I/S108N was
included, but an isolate with mixed codon 51I/59R/
S108N was excluded) were included. At microsatellite
loci around dhps, He was calculated separately among
isolates that contained single infections with the 437 G/
540E mutant allele, and isolates that contained single
infections with the sensitive (wildtype) alleles.
Haplotype characterization
Approximately 70% of the samples used in this study were
‘multiple infections’, i.e. multiple parasite lineages or gen-
omes were present in an infection. Based on dhfr and dhps
genotyping alone, 63.0% and 72.2% were multiple infec-
tions, respectively. The neutral microsatellite markers on
chromosomes 2 and 3 collectively showed that 70.0% of
the samples contained multiple infections, and the micro-
satellites around dhfr and dhps showed 73.9% and 64.5%
multiple infections, respectively. A goal with this study is
to present a population-based perspective and analysis of
McCollum et al. Malaria Journal 2012, 11:77
http://www.malariajournal.com/content/11/1/77
Page 3 of 14
the data; thus, data from multiple infections for appropri-
ate analyses was retained. Multiple infections are inap-
propriate for all of the analyses; and it is stated when data
from multiple infections were excluded.
Microsatellite haplotypes are defined as a collection of
sites close to the genes dhfr and dhps that had low varia-
tion and were more likely to be in linkage disequilibrium.
Thus, 11 microsatellite loci spanning 11.5 kb around dhfr
and nine loci spanning 20 kb around dhps were used to
characterize haplotypes relative to dhfr and dhps alleles.
Haplotypes were classified as different if they contained >
1 different allele across loci. Only samples without mixed
infections detected by pyrosequencing were used for hap-
lotype characterization.
Haplotype analysis
eBURST groups haplotypes, based on a simple evolution
model, which assumes that one lineage or founding hap-
lotype reaches high frequency in the population and then
starts to differentiate, producing closely related haplo-
types; this is depicted as a cluster [27]. Data from the 11
microsatellite loci spanning 11.5 kb around dhfr and nine
loci spanning 20 kb around dhps (as for haplotype char-
acterization) were used to depict genetic relationships in
eBURST. Only samples in which multiple infections were
not detected by pyrosequencing of dhfr or dhps were
used for the eBURST analysis. Since eBURST does not
allow for missing data, samples with incomplete haplo-
types were removed; therefore, there were fewer samples
utilized for the eBURST analysis than for haplotype char-
acterization. If multiple alleles were detected at a single
microsatellite locus in a sample, the most frequent allele
was used, i.e. the one that was present at the highest peak
in the electropherogram.
Genetic differentiation between alleles was measured
using Wright’s F-statistics [28]. The statistic FST mea-
sures genetic differentiation between populations but,
here, FST was used as a statistic to compare groups of
alleles. For dhfr the microsatellite loci from -10 kb to
1.47 kb and for dhps the loci from -2.5 kb to 17.5 kb
were used for the FST analysis. FST calculations were
computed using Arlequin ver 3.01 [29]. The Excel
Microsatellite Toolkit was used to format data for Arle-
quin [30].
Linkage disequilibrium (LD) between loci along the
chromosomes and also between dhfr and dhps point
mutations was assessed by using an exact test of LD
[31]. Samples with multiple alleles at any locus were
removed from the analysis; this was done for dhfr, dhps,
and the neutral markers independently. Similarly, sam-
ples where multiple infections were detected at any site
were removed from the LD analysis, testing pairs of
point mutations in dhfr and dhps; this was done inde-
pendently for dhfr and dhps for a given sample. Only
loci or sites that showed polymorphism among the used
samples were used for the analysis. Associations were
tested between pairs of loci or sites by using 10,000
Monte Carlo steps in Arlequin version 3.01 [29]. To
correct for multiple testing the Bonferroni-Holm correc-
tion was used.
Measuring the strength of selection
The strength of selection on dhfr and dhps was estimated
from the changes in frequency over time of the various
mutant alleles at each gene. The strength of selection, s,
of allele A compared with allele B, was defined as 1 + s
being the average relative reproductive advantage of A
over B [32]. Hence, if pt and pt+T are the relative frequen-
cies of A at times t and t + T, log 1 + s = 1/T (log pt+T/
(1-pt+T)- log pt/(1-pt)) [32].
Measurements for the frequency of the advantageous
allele A were made at time t, pt, at different equally
spaced time points (tk = k*180 days (k = 0, 1, 2...))
within the six years covered by the samples. The fre-
quency at tk was calculated from all samples that were
taken between time tk and tk + 360 days. Hence, the
intervals [tk, tk + 360] overlapped (sliding window). The
strength of selection was obtained by performing a lin-
ear regression of the explanatory variable log pt/(1-pt),
where only those time points tk as regressors for which
at least three triple and three non-triple mutations
occurred were included. The actual strength of selection
per generation is derived from the slope of the linear
regression divided by the number of malaria generations
per year, Ngen, which was assumed to be Ngen = 17.3
(i.e., one transmission cycle every three weeks, corre-
sponding to infections throughout the whole year).
More precisely, if s is the strength of selection, and a
and b are the constant and linear regression coefficients
respectively, log pt/(1-pt) = tNgen log(1 + s)- log p0/(1-p0)
= a+b t. Hence, s = exp(b/Ngen)-1.
Two double mutant dhfr alleles were present in the
Kenyan population, and both confer a level of pyri-
methamine resistance. It is not clear a priori whether
selection for both double mutant alleles is equally
strong; therefore, the strength of selection for 51I/108 N
allele with that for 59R/108 N was compared. The
strength of selection of the triple mutant allele (51I/
59R/108 N) was measured over the 51I/108 N and the
59R/108 N double mutants, separately. For these mea-
surements, only samples with single infections at these
alleles (as detected by pyrosequencing) were included.
The purpose of estimating these three strengths of
selection at dhfr is as follows. If s1, s2, and s3 denote the
strength of selection of 51I/59R/108 N over 51I/108 N,
51I/108 N over 59R/108 N, and 51I/59R/108 N over
59R/108 N, then the standard haploid selection model
yields 1 + s3 = (1 + s2)*(1 + s1).
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Dhps single mutants were at relatively low frequency
and only the 437 G/540E double mutant was found in
single infections. Thus, for dhps, the strength of selec-
tion of double mutant alleles (jointly) was measured
over all other alleles. To derive the frequencies included
were all samples with 437 G/540E single infections, and
all samples that did not contain the mixed codon
A437G/K540E. More precisely, excluded were only
those samples for which it was unclear whether they
contained the 437 G/540E mutant.
The reduction of He flanking dhfr and dhps was utilized
to evaluate whether the estimates for the strengths of
selection were meaningful. For this purpose, He was com-
pared with the analytical prediction He
pred, given by
He
pred = H0 (1-p0
2r(1-F)/s). Here, H0 is the initial expected
heterozygosity, r denotes the recombination rate, F the
inbreeding adjustment (F = 1 corresponds to complete
inbreeding, and F = 0 to random mating), and p0 is the
initial frequency of the 51I/59R/108 N or 51I/108 N
allele, or of the 437 G/540E allele. As in [9-14]r =
5.88*10-4 Morgans/kb and p0 = 10
-4 were used. Also, F =
0.4, which corresponds to 60-70% mixed clone infections
was used. For He
pred among dhps 437 G/540E alleles, He
among wildtype alleles was used as an estimate for H0,
since it should not be affected by the sweep. For He
pred
among 51I/59R/108 N alleles, He among double, single
mutant and wildtype alleles was used as an estimate for
H0. For He
pred among 51I/108 N double mutants, He
among 59R/108 N double, single mutant and wildtype
alleles was used as an estimate for H0.
Results
Genotyping results
The frequency of dhfr and dhps alleles in the sample set
was calculated with two analyses: a) including only sin-
gle infections as determined by pyrosequencing of the
mutations in dhfr or dhps, and b) including both the
single and multiple infections that exhibited only one
codon with two amino acids. For the latter, the “multi-
ple” allele codon was used to break down the allele into
two separate alleles (e.g. N51/59R/S108N was analysed
as N51/59R/S108 and N51/59R/108 N). The frequency
of mutant alleles is strikingly similar for the two ana-
lyses (Figure 1), but for consistency the frequency of the
“single infection” sample set will be emphasized here.
There were very few sensitive wildtype dhfr alleles in
the population (3%), and the majority of the sample set
is composed of double (50% 51I/108 N, 27% 59R/108
N) or triple mutant (20%) dhfr alleles. The majority of
dhps alleles were sensitive wildtype (34%) and 437
G/540E mutants (57%). For both dhfr and dhps, the
majority of the mutant alleles were double or triple
mutant alleles.
Haplotype analysis
In an attempt to better understand the evolutionary his-
tory of the alleles in the population, microsatellite hap-
lotypes were characterized for the microsatellite loci
immediately surrounding dhfr and dhps (Additional file
2: Figure S1 and Additional file 3: Figure S2, respec-
tively). There were 25 haplotypes for the dhfr double
mutant 59R/108 N (n = 40) and 23 haplotypes for the
double mutant 51I/108 N (n = 72). The 59R/108 N
allele is not dominated by any particular haplotype;
however, the 51I/108 N allele is dominated by one hap-
lotype at high frequency (haplotype 26, 64%).
Six haplotypes for the dhfr triple mutant (51I/59R/108
N) allele (n = 29) were observed. Two haplotypes (15 and
17) were seen in three of the triple mutant allele samples
that are also represented in allele 59R/108 N. The remain-
ing four haplotypes (48 - 51) are not present for either of
the double mutant alleles; they are unique to the triple
mutant allele. Haplotype 48 is the most predominant hap-
lotype for the triple mutant allele (79%) and is identical or
closely related to the previously characterized Southeast
Asian triple mutant dhfr haplotype [9,11]. The triple
mutant dhfr alleles in this population also have three addi-
tional unique haplotypes, 49, 50, and 51; each present in
one sample.
Haplotype analysis for dhps revealed 54 haplotypes for
the wildtype allele (n = 57) and 13 haplotypes for the
double mutant allele 437 G/540E (n = 95). There were
no predominant haplotypes for wildtype alleles. For the
samples containing the 437 G/540E allele, however, hap-
lotype 55 was present at a high frequency (86%).
Genetic differentiation and relationships among
haplotypes and alleles
The FST values for the comparisons between the three
multiple mutant alleles of dhfr (51I/108 N, 59R/108 N,
51I/59R/108 N) were high and significant (p < 0.01).
There was also a significant value for the comparison
between the dhps wildtype and 437 G/540E double
mutant alleles (p < 0.01).
The application eBURST was used to discern relation-
ships among the dhfr and dhps microsatellite haplotypes.
The analysis for dhfr was conducted by combining the
data from this study with dhfr haplotypes previously
reported from the same region of western Kenya in 38
samples collected in 2002-2004, almost 10 years after
the samples used by this study were collected [15]. The
majority of the dhfr double mutant haplotypes from
2002-2004 were present in the earlier set of samples
(Additional file 4: Figure S3). A large 51I/59R/108 N
cluster is comprised entirely of haplotype 48, which was
the most prevalent haplotype found for the triple
mutant dhfr allele, with the addition of rare independent
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Figure 1 Frequency of dhfr (A) and dhps (B) alleles in the sample set. Bars represent the frequency in “single infections” as detected by
genotyping (dhfr n = 145 and dhps n = 166), and the frequency of the alleles in “mixed infections” - single infections plus multiple infection
where only one codon was a mixture of wildtype and mutant codons (dhfr n = 205 and dhps n = 217).
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haplotypes from 2002-2004 [11]. The minor frequency
triple mutant allele haplotypes 17, 49, 50, and 51 are
not closely related to the major frequency haplotype
(haplotype 48).
An analysis of dhps haplotypes exhibits a single cluster
comprised entirely of haplotypes from the double
mutant alleles (Additional file 5: Figure S4). Specifically,
all points are derived from haplotype 55, which is the
haplotype in highest frequency from the 437 G/540E
sample set (Additional file 3: Figure S2).
Estimates of selection
Using linear regression, the 51I/59R/108 N allele has a
selective advantage over both double mutant alleles at
dhfr: s1 = 0.013 (± 0.004) over the 51I/108 N allele
(Figure 2A), and s2 = 0.036 (± 0.007) over the 59R/108
N allele (Figure 2B). Note that s2 is a lower bound for
the selective advantage of the 51I/59R/108 N allele over
the (extinct) wildtype. Furthermore, the 51I/108 N allele
has a selective advantage of s3 = 0.021 (± 0.005) over
59R/108 N allele (Figure 2B). These estimates are con-
sistent since 1 + s3≈(1 + s2)*(1 + s1). At dhps, the 437
G/540E allele has a selective advantage s = 0.009 (±
0.002) over wildtype alleles (Figure 2A).
Variation around genes under selection
The pattern of genetic variation linked to dhfr and dhps
was examined. Number of alleles per locus (A) and het-
erozygosity (He) was calculated as a measure of variation
at each microsatellite locus (Additional file 6: Table S2).
The number of alleles found at each microsatellite locus
around dhfr and dhps alleles is shown in Additional file 7:
Figure S5. There is a stronger reduction in He surrounding
dhfr 51I/59R/108 N and 51I/108 N alleles, than the 59R/
108 N allele (Figure 3A). A significant reduction in He is
observed around dhps 437 G/540E mutant allele com-
pared to the wildtype allele (Figure 3B).
The observed He among dhfr 51I/59R/108 N alleles and
dhps 437 G/540E alleles was compared to the He pre-
dicted by a standard selective sweep model [33], using
the estimates for selection coefficients. Similar models
have been used elsewhere [9,21]; however, these assume
that the beneficial allele has reached a frequency of nearly
100%. As an estimate for the strength of selection, s =
0.036 was used, which is a lower estimate for selective
advantage of the triple mutant over the wildtype. The
initial He for dhfr could not be estimated because sensi-
tive wildtype alleles were present only at marginal fre-
quencies. Therefore, the initial He was set to He among
infections without the triple mutant (including infections
with the mixed codons N51I/S108N or C59R/S108N.
The prediction underestimates He for parasites carrying
the 51I/59R/108 N triple mutant at dhfr (Additional file
8: Figure S6). This can be due to the assumption of 17.3
transmissions per year, which leads likely to underesti-
mates of selection.
At dhps the pattern of observed He is in general agree-
ment with the predicted heterozygosity (Additional file 6:
Table S2). He 3’ to the gene is much higher than the
actual observation; however, this is typical for selective
sweeps that the valley of reduced heterozygosity is much
more pronounced on one side of the target of selection
[34].
The pattern of linkage disequilibrium (LD) in the chro-
mosomal region surrounding dhfr and dhps is another
measure of strong selection in the population (Additional
file 9: Figure S7). In addition, LD between the codons
involved in drug resistance of dhfr and dhps was exam-
ined. There was significant LD between codons 437 and
540 of dhps (Additional file 9: Figure S7).
Discussion
Allele populations: genetic differentiation and divergence
Western Kenya is an area of intense transmission with an
entomological inoculation rate (EIR) of approximately
300 infective bites per person per year during the early
1990s, before the introduction of bed nets [25]. There-
fore, there will be many multiple ‘strain’ infections (as
many as 70% of the samples collected in this study as
measured by the neutral microsatellite markers) and, as a
consequence, a great amount of meiotic recombination.
The large amount of recombination along with histori-
cally older parasite populations in Africa contributes to a
large amount of variation in term of the number of differ-
ent genetic lineages circulating in the population. Conse-
quently, reconstructing a pattern of descent is difficult to
do with absolute precision. Nevertheless, the data sup-
port an overall pattern of genetic differentiation between
the major mutant alleles of dhfr and the dhps double
mutant allele from any wildtype alleles in the population.
Genetic differentiation between dhfr alleles was main-
tained over time. The data suggest that the 51I/108 N
and 51I/59R/108 N alleles have remained distinct in the
population. This can be explained by stronger selection
for the 51I/59R/108 N, and the fact that the majority of
these alleles were imported from Southeast Asia along a
haplotype, which was not present in Kenya. Similarly,
genetic differentiation between dhfr alleles in a Cameroo-
nian population was previously noted [14].
The most predominant dhfr triple mutant haplotype in
both sample sets (Kenya and Cameroon) was one pre-
viously described in Southeast Asia and has since been
documented in multiple sites across Africa, including
eastern Kenya [9,10,12,13,15]. This Southeast Asian hap-
lotype appears to have diverged over time in the western
Kenyan population; this result is expected for an allele
that has been in a population for many years. The highly
resistant Southeast Asian lineage is the most prevalent
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triple mutant dhfr lineage in both the 2002-2004 and
1992-1999 sample sets, which is consistent with studies
suggesting that the Southeast Asian haplotype is the only
one present in African populations [11-13]. Furthermore,
a study from eastern Kenya showed only the Southeast
Asian lineage for all triple mutant alleles, and this lineage
was present as early as 1988 [13]. Here, this lineage is
documented in western Kenya as early as 1992. The
Figure 2 Estimates for the strength of selection. (A) 437 G/540E vs wildtype at dhps and 51I/59R/108 N vs 51I/108 N at dhfr. (B) 51I/108 N vs
59R/108 N and 51I/59R/108 N vs 59R/108 N at dhfr.
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mechanisms that allowed the minor and major variant
triple mutant alleles to emerge and be maintained over
time cannot be completely characterized at this time
since there is a paucity of serial samples from the time
period prior to the widespread use of SP. Theoretically, it
is possible that the triple mutant was created by mutation
Figure 3 A) Observed He at ms loci around dhfr alleles 51I/59R/108 N, 51I/108 N, and 59R/108 N. B). Observed He around dhps wildtype
and 437 G/540E alleles. Here, He is calculated from single infections only. Loci are named according to their positions relative to dhfr or dhps (kb
from the gene). The sampling variance is indicated by error bars. Dashed horizontal line indicates the average He from chromosomes 2 and 3.
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from a rare haplotype, which is similar to the Asian hap-
lotype but too infrequent to be detected in the sample,
and spread to high frequency; however, this alternative is
highly unlikely.
The double mutant dhfr and dhps alleles are also illu-
minating. There is a larger number of haplotypes for
these alleles than has been documented at other sites in
Africa [10,13]. There are, however, fewer haplotypes for
the triple mutant dhfr allele than for the double mutants
and fewer haplotypes for the mutant dhps allele than the
wildtype allele: results which are consistent with the
hypotheses that selection is stronger on the alleles with
fewer haplotypes or that these alleles are newer in the
population [14,19]. Moreover, more haplotypes were
found for the 59R/108 N allele than the 51I/108 N
allele, and this is consistent with results that selection
on the latter allele is stronger. Namely, for the 51I/108
N mutant (i) recombination breaks down the initial
association with the ancestral haplotype less efficiently,
and (ii) the time window in which recurrent mutations
can occur and rise to detectible frequency is narrower.
Hitchhiking and linkage disequilibrium
The shape of the curve of variation around genes under
strong selection is affected by a number of factors includ-
ing the strength of selection, time since the initial selec-
tive event, and the amount of recombination [32,35].
This asymmetry is consistent with hitchhiking models
even when the rates of recombination and mutation are
constant [34]. The asymmetry seen in the lack of varia-
tion surrounding dhfr and dhps has been documented
previously for dhfr [19,21]. The peaks in He around the
dhfr triple mutant compared with the 51I/108 N double
mutant at some microsatellite loci are consistent with the
evidence that the triple mutant was imported from
Southeast Asia. Namely, imported microsatellite alleles
(which were not existing in Kenya) could have hitchhiked
with the triple mutant, resulting in relatively large He.
If resistant alleles confer a selective advantage, one can
hypothesize that the genetic variation around these alleles
would be substantially reduced as a result of stronger
selection compared to the wildtype or less resistant/toler-
ant alleles in the population. This has been demonstrated
in African P. falciparum populations previously for dhfr
[19] and dhps [17]. The population of dhfr and dhps alleles
in western Kenya shows dramatic levels of LD around
both genes compared to neutral markers. This is expected
under conditions of very strong natural selection, such as
those that might occur in environments that promote the
rise of drug resistance. Theoretical evidence supports the
hypothesis that LD will decay rapidly after a hitchhiking
event [36,37]. Here, there is LD for approximately 20 kb
around both dhfr and dhps. A more advanced theoretical
model is needed to evaluate the patterns seen here in wes-
tern Kenya.
The data here do not demonstrate significant LD
between mutant dhfr and dhps alleles - another line of
evidence suggesting that selection has not occurred on
any two mutant alleles at a given point in time in the
population; i.e. selection on dhfr alleles is likely indepen-
dent of that on dhps alleles. This finding suggests that, in
a holoendemic area with high recombination, a multi-
drug-resistant haplotype is less likely to be maintained in
the absence of drug pressure, as has been the case in
areas with low transmission [20]. Additionally, since SP
was a second-line treatment, joined selection pressure on
dhfr and dhps must have been weaker (in the overall
population) than as if it was the first-line treatment.
Again, this increases the chance of meiotic recombina-
tion between dhfr and dhps.
Selective sweeps
Sulphadoxine-pyrimethamine resistance in the Asembo
Bay area was reported in the literature as early as 1982;
therefore, the high proportion of mutant dhfr and dhps
alleles in the population is not surprising [23]. Since the
data used in this study provides longitudinal information,
it was possible to directly estimate the selective para-
meters from the frequency changes in the various muta-
tions. Notably, a theoretical model [38,39] tailored to
P. falciparum justifies this approach. Thus, the results
presented here are the first estimates of selective para-
meters from molecular data in Africa and the first for
dhps. The results for dhps, in contrast to dhfr, revealed a
greater proportion of wildtype alleles in the population.
Similar data have been noted in previous studies, and
Nzila et al. [40] have suggested that after the triple
mutant dhfr alleles spread sufficiently through a popula-
tion, dhps mutant alleles increase in frequency due to
selection by sulphadoxine [14,40,41]. While dhfr double
mutants were predominantly present, triple mutants
increased in frequency from 1992-1999, in accordance
with positive selection for those mutants. Sulphadoxine-
sensitive wildtype dhps alleles were still present at appre-
ciable frequency, while resistant mutant alleles increased
in frequency during this observed time period.
Further evidence for strong selection for the double
mutant allele is the loss of variation around dhps 437 G/
540E allele as well as high levels of LD around dhps. It
appears as though this study has captured the dhps 437 G/
540E alleles in the middle of a selective sweep, i.e. while its
frequency increases in the population. The data suggest
that this population in western Kenya possibly experienced
dramatically strong selection events leading to a rapid
increase in frequency of resistant dhfr alleles, but such
events took place before drug selection allowed for the rise
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in frequency of dhps resistant alleles. Indeed, this hypoth-
esis is consistent with previous studies [1,17,42]. It would
be interesting to assay this population again based on
more recent samples to observe how shape and depth of
the heterozygosity as well as the frequency spectrum of
resistant mutations have changed as a result of a change
in drug policy. In particular, by employing the regression
approach presented here, it would be possible to estimate
the amount of metabolic costs associated with drug-resis-
tance of various dhfr and dhps mutations in natural
settings.
Soft selective sweeps, as opposed to the traditional
“hard” selective sweep proposed by Maynard Smith and
Haigh [32], are a case where multiple alleles are favoured
by selection and, consequently, multiple genetic back-
grounds hitchhike with the alleles under selection
[43,44]. The result will be an increase in the amount of
variation surrounding the selected allele as compared to
a hard selective sweep. The presence of different predo-
minant haplotypes for dhfr alleles together with reduced
variation along the chromosome for each of these is evi-
dence of selection on each of these alleles - a soft selec-
tive sweep.
Typically, the classical “hard” sweep of the Southeast
Asian triple mutant allele has been suggested for dhfr
alleles. These arguments, however, do not describe the
dynamics of drug resistant mutations for Plasmodium,
especially in Africa. This study has led to the hypothesis
that soft sweeps involving drug resistant alleles should be
more common in Africa since drug pressure is effectively
lower. Indeed, there is a higher proportion of asympto-
matic (untreated) infections due to higher levels of
acquired immunity. It is worth noting that the data from
[10] is suggestive of a soft sweep in South African and
Tanzanian populations. Nevertheless, understanding the
factors leading to soft sweeps for pyrimethamine resis-
tance, and any other form of drug resistance that involves
such a complex pattern of alleles, requires more studies.
Multiple origins and soft sweeps are expected to be
common if mutation rates are high or population sizes are
large; specifically if the population-based mutation para-
meter 2Neμ > 0.01 [43]. The mutation rate for pyrimetha-
mine resistance has been estimated to be 10-9 [45] and the
estimated population size for African P. falciparum popu-
lations based on mtDNA sequence variation is about 105
[46,47]. Given these estimates (2Neμ = 2 × 10
-4), a first
approximation is that soft sweeps are expected to be rare
[43]. Note that estimates for Ne may have limited mean-
ing, since these estimates reflect the fact that some charac-
teristic is equivalent to a Wright-Fisher model with
sample size Ne. The complexity of the P. falciparum trans-
mission cycle implies that there are processes that exceed
the simplicity of standard population genetic assumptions
[38]. However, the population-genetic analyses performed
in this article are justified by the theoretical results of
Schneider and Kim [38,39]. Summarizing, soft sweeps
might be more common than naively expected.
Strength of selection
In [9], a similar approach as here was used to estimate
the selective strength at dhfr in a Southeast Asian popu-
lation; however, there are crucial differences. The
strength of selection was estimated from genetic data,
whereas the prior study used historic data from clinical
treatment failures and clinical success. The latter is pro-
blematic, because clinical failures do not directly corre-
late with the presence of resistant mutations and there
could be multiple variables affecting a patient’s treatment
outcome. Moreover, the data are acquired from sympto-
matic infections (asymptomatic infections do not need
treatment), which implies an overestimation of the
strength of selection since it masks the disadvantage of
resistance due to metabolic costs that are only apparent
in untreated infections. Notably, the use of longitudinal
data allowed for a comprehensive analysis on the
strength of selection acting on specific mutants rather
than an overall average of selection. Nair et al. [9]
assumed six transmission cycles per year and an inbreed-
ing adjustment factor of 80%; parameters that properly
describe an area with lower transmission and lower fre-
quency of multiple infections but do not properly
describe holo-endemic areas such as western Kenya. In
this case, 17.3 transmission cycles per year were used,
which, assuming an incubation period of three weeks
corresponds to infections over the entire course of a year.
The choice of 21 days was based on the extremely high
transmission rates, the fact that a mosquito becomes
infective approximately 10 days after the blood meal, and
that it will take seven to 11 days until gametocytaemia
peaks in infected patients. Also the inbreeding was
adjusted to 40%, which is in agreement with the percen-
tage of observed multiple infections (63%-70%). Whereas
the absolute values of s depend on these assumptions,
the relative pattern observed does not. Nevertheless, it is
straightforward to re-calculate s assuming different num-
bers of transmission cycles per year (see methods). It is
worth nothing that there is not such a thing as a univer-
sal “s“; thus, conclusions should be made based on gen-
eral patterns and relative differences at a local level.
For the purpose of estimating the selective strengths,
sample sizes were rather small due to multiple infections
and the inability to discern alleles; however, an approach
was pursued that included as many isolates as possible.
Regardless of its limitations, the results clearly indicate
that drug selection due to a combination drug therapy
operates differently at each individual locus, and for indi-
vidual alleles per locus. Overall, the study provides direct
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temporal evidence of differential selection acting on dhfr
and dhps mutations associated with resistance in Africa.
Conclusions
The three signatures of a selective sweep in a population:
altered distribution of polymorphic sites along the chro-
mosome, altered allele frequency spectrum, and an
increase in the amount of linkage disequilibrium, are all
seen in dhfr and dhps allele populations in western Kenya.
The independent origination, genetic differentiation, and
maintenance of alleles allude to the fact that rapid,
dynamic events in the clinical and ecological settings have
given rise to the patterns of resistant mutations we see
today. Regardless of the fact that SP is a combination drug
therapy, the strength of selection on the two loci is differ-
ent and the drug by itself does not appear to select for
“multidrug"-resistant parasites in areas with high recombi-
nation rate. The various estimates for the selective
strengths on various mutant alleles, allow for a more com-
plete understanding of the evolutionary dynamics asso-
ciated with drug-resistance. Thus, the local demographic
history (effective population size and recombination rate)
needs to be taken into account when investigating the rise
of multi-resistant genotypes in Plasmodium populations.
Additional material
Additional file 1: Table S1. PCR primers used for dhps microsatellite
amplification.
Additional file 2: Figure S1. Haplotype frequencies for dhfr alleles: A)
59R/108N (n = 40), B) 51I/108N (n = 72), and C) 51I/59R/108N (n = 26).
Haplotypes are along the X axis and frequency in the sample set is along
the y axis.
Additional file 3: Figure S2. Haplotype frequencies for dhps alleles: A)
wildtype (n = 57) and B) 437G/540E (n = 95). Haplotypes are along the X
axis and frequency in the sample set is along the y axis.
Additional file 4: Figure S3. Relationships among 95 8-locus dhfr
microsatellite haplotypes from populations in Western Kenya as
determined by eBURST analysis. Samples from 1992-1999 (n = 134
samples) and 2002-2004 (n = 37 samples) were used. Each line connects
haplotypes that are identical at 7 of 8 loci. The size of the circles is
proportional to the number of isolates of the given haplotype. The blue
circles represent founders for the clusters and the yellow circle represent
subgroup founders. Black circles without any shading represent
haplotypes only present for the samples collected in 1992-1999, green
shading represents haplotypes present only in the 2002-2004 collection,
and pink shading represents haplotypes present in both collections. 51I/
59R/108N haplotypes circled in red are triple mutants that originated
independently from the SE Asian haplotype. Two genotypes that include
the mutation 164L are noted not being connected to any other
haplotype.
Additional file 5: Figure S4. Relationships among 128 9-locus dhps
microsatellite haplotypes from western Kenya as determined by eBURST
analysis. Each line connects haplotypes that are identical at 8 out of 9
loci. The size of the circles is proportional to the number of isolates of
the given haplotype. Haplotypes shown as single points differ from the
other haplotypes by alleles in at least 2 loci. The central complex
represents haplotypes from the 437G/540E allele. A total of 44 samples
with the wildtype allele and 84 samples with the 437G/540E allele were
utilized for this analysis.
Additional file 6: Table S2. Number of alleles (A) and heterozygosity
(He) per locus and averaged over loci.
Additional file 7: Figure S5. Relationships among 128 9-locus dhps
microsatellite haplotypes from western Kenya as determined by eBURST
analysis. Each line connects haplotypes that are identical at 8 out of 9
loci. The size of the circles is proportional to the number of isolates of
the given haplotype. Haplotypes shown as single points differ from the
other haplotypes by alleles in at least 2 loci. The central complex
represents haplotypes from the 437G/540E allele. A total of 44 samples
with the wildtype allele and 84 samples with the 437G/540E allele were
utilized for this analysis.
Additional file 8: Figure S6. Observed and predicted He at ms loci
around the (A) dhfr allele 51I/59R/108N and (B) dhps allele 437G/540E.
For the dhfr prediction (A) we used He among all samples that did not
include the 51I/59R/108N triple mutant (i.e. infections with the mixed
codons N51I/S108N and C59R/S108N were included). For the dhps
prediction (B) we used He among wildtype alleles as an estimate for the
initial heterozygosity. Loci are labelled according to their positions
relative to dhfr or dhps (kb from the gene). Sampling variance is
indicated by error bars.
Additional file 9: Figure S7. Pairwise LD between microsatellite loci on
different chromosomes (A) and between sites in dhfr and dhps (B). Each
cell represents one comparison between polymorphic pairs of loci. Gray
cells represent significance at p value < 0.01. (A) The position of dhfr and
dhps along the chromosome is denoted by the gray bar. The location of
each microsatellite locus is at the top of the matrix (loci are named
according to their positions relative to dhfr or dhps or along
chromosome 2 or 3 according to the 3D7 genome sequence available
from NCBI). (B) Pairwise LD between sites in dhfr (51, 59, 108) and dhps
(436, 437, 540).
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